Presentation and risk stratification - improving prognosis for patients with multiple myeloma

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 2, 2010, Pages

  Lonial, Sagar ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytogenetics; Diagnosis; Multiple myeloma; Prognosis; Risk stratification

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; M PROTEIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; KIDNEY DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RISK REDUCTION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; HUMANS; MULTIPLE MYELOMA; PILOT PROJECTS; PROGNOSIS; RENAL INSUFFICIENCY; RISK;

EID: 77952795435     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70007-4     Document Type: Article

References (64)

1. Munshi NC Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program 2008, 297.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC Multiple myeloma. Lancet 2009, 374:324-339.
3. Reece DE Recent trends in the management of newly diagnosed multiple myeloma. Curr Opin Hematol 2009, 16:306-312.
4. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33.
5. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757.
6. Dispenzieri A, Kyle RA Multiple myeloma: clinical features and indications for therapy. Best Pract Res Clin Haematol 2005, 18:553-568.
7. Harousseau JL, Dreyling M, ESMO Guidelines Working Group Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl 2):ii55-ii57.
8. NCCN NCCN Practice Guidelines in Oncology: Multiple Myeloma, V.3.2010 Accessed April 2010. http://www.nccn.org.
9. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009, 23:1716-1730.
10. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224.
11. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007, 137:49-63.
12. Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006, 132:410-451.
13. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009, 23:1545-1556.
14. Durie BG, Salmon SE A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
15. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
16. Mihou D, Katodritou I, Zervas K Evaluation of five staging systems in 470 patients with multiple myeloma. Haematologica 2006, 91:1149-1150.
17. Scudla V, Zemanova M, Minarik J, et al. International prognostic index (IPI) - a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy. Neoplasma 2006, 53:277-284.
18. Hari PN, Zhang MJ, Roy V, et al. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 2009, 23:1528-1534.
19. Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009, 46:110-117.
20. Kyle RA, Rajkumar SV Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
21. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009, 23:1152-1157.
22. Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
23. Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010, 28:690-697.
24. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007, 356:2582-2590.
25. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008, 111:785-789.
26. Avet-Loiseau H, Durie BG, Haessler J, et al. Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG Analysis of 9,897 patients [abstract]. Blood 2009, 114. abstract 743.
27. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain melanoma. Clin Chem 2002, 48:655-657.
28. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007, 110:827-832.
29. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007, 137:240-243.
30. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008, 22:1933-1937.
31. Zhan F, Bryant B, Barlogie B, Mulligan G, Shaughnessy JD A gene expression-based risk stratification model developed in newly diagnosed multiple myeloma treated with high dose therapy is predictive of outcome in relapsed disease treated with single agent bortezomib [abstract]. Blood 2007, 110. abstract 656.
32. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD, Bryant B High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 2008, 111:968-969.
33. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
34. Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009, 27:4197-4203.
35. Nair B, van Rhee F, Shaughnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood 2010 Feb 2, [Epub ahead of print].
36. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007, 25:1993-1999.
37. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
38. Brenner H, Gondos A, Pulte D Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
39. Brenner H, Gondos A, Pulte D Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94:270-275.
40. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
41. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23:2147-2152.
42. Rajkumar SV, Kyle RA Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005, 80:1371-1382.
43. Rajkumar SV, Buadi F Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007, 20:665-680.
44. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 2008, 111:4039-4047.
45. Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009, 83:519-527.
46. Revlimid® (lenalidomide) prescribing information Accessed 31 March 2010. http://www.revlimid.com/pdf/REVLIMID_PI.pdf.
47. Gladney SP, Lonial S, Kaufman JL Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clin Lymphoma Myeloma 2008, 8:52-54.
48. Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008, 49:890-895.
49. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109:3489-3495.
50. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma (MM) with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities [abstract]. Blood 2009, 114. abstract 958.
51. Avet-Loiseau H, Leleu X, Roussel M, et al. Deletion of the 17p chromosomal region is associated with a very poor outcome in multiple myeloma independently of the type of treatment [abstract]. Blood 2009, 114. abstract 1817.
52. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114:522-525.
53. Avet Loiseau H, Moreau P, Mathiot C, et al. Induction with Velcade®/dexamethasone partially overcomes the poor prognosis of t(4;14), but not that of del(17p), in young patients with multiple myeloma [abstract]. Blood 2009, 114. abstract 957.
54. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007, 137:429-435.
55. Chanan-Khan A, Dimopoulos MA, Weber DM, et al. Safety and efficacy outcomes with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma were not significantly different for the treatment of patients with or without high-risk disease or elderly status [abstract]. Blood 2008, 112. abstract 3701.
56. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 2006, 47:803-814.
57. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007, 31:779-782.
58. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
59. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007, 21:164-168.
60. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009, 114:518-521.
61. Mateos M-V, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years [abstract]. Blood 2009, 114. abstract 3.
62. Harousseau J-L, Avet-Loiseau H, Attal M, et al. High complete and very good partial response rates with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial [abstract]. Blood 2009, 114. abstract 353.
63. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients [abstract]. Blood 2009, 114. abstract 128.
64. 2) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: an interim analysis [abstract]. Blood 2009, 114. abstract 350.